Abstract
Objective: Amplification of CCNE1 is present in ~20% of high-grade serous cancers of gynecologic origin (HGSC) and is associated with chemotherapy resistance and poor prognosis. The timing of amplification in serous tumorigenesis and heterogeneity across anatomic sites is unclear. We characterized CCNE1 amplifications among multiple anatomic sites to understand disease heterogeneity and implications for treatment resistance.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
